The study to develop novel treatment for antibody-mediated rejection after organ transplantation. - RIT-DSA-T

Egawa Hiroto0 个研究点目标入组 14 人开始时间: 2019年3月13日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 14

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

All patients received rituximab. Safety: No unlisted serious side effects were observed. Efficacy: Sensitized cases before transplantation: The efficacy was showed. (pre-transplant desensitization purpose) The cases with antibody-mediated rejection: The efficacy was suggested. But the efficacy was poor in cases of graft dysfunction.

研究设计

研究类型: Interventional

入排标准

年龄范围: ot applicable 至 ot applicable（—）
性别: All

入选标准

•1. Sensitized cases before transplantation: Positive of antibody for HLA and awaiting for the organ transplantation including liver, heart, pancreas/islet or small intestine.
•2. The cases with antibody-mediated rejection: With ongoing AMR after organ transplantation including liver, heart, lung, pancreas/islet or small intestine.
•3. Under fully informed consent with legal representative.

排除标准

•1. The cases with active infection.
•2. The cases with viable malignancy, excluding hepatocellular carcinoma which is rescued by liver transplantation.

研究者

发起方

Egawa Hiroto

相似试验

终止

2 期

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid ArthritisRheumatoid Arthritis

NCT00298272Biogen54

进行中（未招募）

1 期

Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitis

EUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106

已完成

不适用

A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndrome

JPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10

未知

2 期

Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathy

JPRN-UMIN000024612Gunma University10

Unknown

4 期

Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus ErythematosusAutoimmune Diseases

NCT04127747Second Affiliated Hospital, School of Medicine, Zhejiang University110